secwatch.observer — SEC 8-K summary
======================================

Issuer:     Werewolf Therapeutics, Inc. (HOWL)
CIK:        0001785530
Form:       8-K
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0001785530-23-000027
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Werewolf Therapeutics Q2 net loss narrows to $5.1M; cash runway through Q4 2024; WTX-124 data expected 4Q23
--------------------------------------------------------------------------------

- Net loss $5.1M ($0.16/diluted share) vs $14.6M ($0.83) in Q2 2022; collaboration revenue $8.1M (up from $4.1M).
- Cash and equivalents $137.5M at June 30, 2023; restricted cash $21.2M; runway through at least Q4 2024.
- R&D expenses fell to $9.6M from $13.9M YoY on lower manufacturing costs and purchase-order closeouts.
- WTX-124 Phase 1/1b enrollment ongoing; initial monotherapy safety, PK, and biomarker data anticipated in 4Q 2023.
- Jazz Pharmaceuticals' JZP898 (formerly WTX-613) IND cleared July 2023 under the Werewolf collaboration.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1785530/000178553023000027/0001785530-23-000027-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1785530/000178553023000027/howl-20230810.htm
  HTML page:      https://secwatch.observer/filing/0001785530-23-000027

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer